Opportunity Information: Apply for PAR 24 300
The Behavioral and Integrative Treatment Development Program (R34 Clinical Trial Optional), funding opportunity number PAR-24-300, is a National Institutes of Health (NIH) discretionary grant designed to support early, focused research that develops and refines behavioral interventions related to substance use and addiction. The central aim is to move promising behavioral approaches toward stronger evidence by testing efficacy and, when appropriate, conducting clinical trials. This FOA is especially geared toward intervention development work that goes beyond simply asking whether something works; it also emphasizes understanding how and why an intervention works, what "dose" or intensity is needed to produce benefit, and how to optimize treatment components so programs are more effective and scalable in real-world settings.
A major theme of the program is integrative and strategic treatment design. NIH is seeking studies that help determine the best sequencing and combination of interventions, including behavioral approaches used alone, paired with medications, delivered sequentially, or integrated into a coordinated model. This includes drug abuse treatment interventions for people with co-occurring conditions (comorbidities), recognizing that many patients receiving substance use treatment also face mental health disorders, medical complications, or social and structural barriers that affect outcomes. The FOA also highlights treatment adherence as a key research focus, supporting projects that improve engagement, retention, and consistent participation in drug abuse treatment and related care.
Technology-enabled interventions are explicitly encouraged, particularly when technology can strengthen outcomes while also making programs easier to implement and sustain. That can include digital tools that increase adherence, extend support outside clinic visits, improve monitoring and feedback, or reduce burden on staff while maintaining fidelity to an evidence-based protocol. The opportunity also prioritizes research that addresses HIV prevention within drug abuse treatment settings, specifically interventions that reduce HIV acquisition or transmission risk among individuals in treatment. In addition, it supports work aimed at improving adherence not only to substance use treatment, but also to HIV medications and addiction medications, reflecting the reality that medication adherence is often a decisive factor in long-term outcomes.
Another highlighted area is the intersection of substance misuse and chronic pain. The FOA welcomes intervention development research that treats substance misuse in the context of chronic pain, which often requires carefully balanced approaches that address pain management, functioning, and risk of misuse simultaneously. Across all these topics, the announcement notes that research of interest includes, but is not limited to, Stage I research, indicating an emphasis on early-stage behavioral treatment development activities such as refining intervention components, testing feasibility and acceptability, and generating preliminary signals of efficacy and mechanism before larger-scale trials.
The grant mechanism is R34, with clinical trials listed as optional, meaning applicants can propose projects that include a clinical trial component when it is justified by the development stage and research questions, but the mechanism also accommodates intervention development work that may not require a full clinical trial design. The program sits within NIH health and education activity areas and is associated with CFDA numbers 93.273 and 93.279.
Eligibility is broad and includes many types of U.S. organizations and government entities. Eligible applicants include state, county, city or township governments, special district governments, independent school districts, public and state-controlled institutions of higher education, private institutions of higher education, and a range of nonprofit organizations (both with and without 501(c)(3) status). For-profit organizations (other than small businesses) and small businesses are also eligible, along with public housing authorities and Indian housing authorities. Tribal eligibility includes federally recognized Native American tribal governments and Native American tribal organizations that are not federally recognized governments. The FOA also calls out additional eligible applicant categories such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISI), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, regional organizations, U.S. territories or possessions, eligible federal government agencies, and even non-U.S. entities (foreign organizations), signaling an intent to support diverse institutional contexts and communities.
Key administrative details from the listing include an original closing date of 2025-05-07 and a creation date of 2025-01-22. An award ceiling is not specified in the provided source data, and the expected number of awards is also not listed here. Overall, the opportunity is best suited for teams developing practical, mechanism-informed behavioral or integrated interventions for substance use treatment, adherence, HIV-related risk reduction in treatment populations, and substance misuse with chronic pain, with a clear pathway toward optimized, implementable, and sustainable treatment strategies.Apply for PAR 24 300
- The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "Behavioral and Integrative Treatment Development Program (R34 Clinical Trial Optional)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.273, 93.279.
- This funding opportunity was created on 2025-01-22.
- Applicants must submit their applications by 2025-05-07. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is the name of this funding opportunity?
The opportunity is the Behavioral and Integrative Treatment Development Program (R34 Clinical Trial Optional).
What is the funding opportunity number (FOA number)?
The FOA number is PAR-24-300.
Which agency is offering this grant?
This is a National Institutes of Health (NIH) discretionary grant.
What is the main purpose of this program?
The program supports early, focused research to develop and refine behavioral interventions related to substance use and addiction. The goal is to move promising approaches toward stronger evidence by testing efficacy and, when appropriate, conducting clinical trials.
What kind of research does the program emphasize beyond basic efficacy testing?
The program emphasizes understanding how and why an intervention works, identifying what "dose" (intensity) is needed to produce benefit, and optimizing treatment components so interventions are more effective and scalable in real-world settings.
What grant mechanism is used for this opportunity?
The mechanism is R34.
Are clinical trials required under this opportunity?
No. Clinical trials are listed as optional. Applicants may include a clinical trial component when justified by the development stage and research questions, but projects may also focus on intervention development work that does not require a full clinical trial design.
What does "Clinical Trial Optional" mean in practice for applicants?
It means the FOA accommodates both (1) development work that may not be structured as a clinical trial and (2) projects that include a clinical trial when that approach is appropriate for testing efficacy during intervention development.
What types of interventions are the focus of this FOA?
The FOA focuses on behavioral interventions related to substance use and addiction, including integrative approaches that combine or sequence behavioral and medication-based strategies.
What does the FOA mean by "integrative and strategic treatment design"?
It refers to studies designed to determine the best sequencing and combination of interventions, such as behavioral approaches used alone, paired with medications, delivered sequentially, or integrated into a coordinated model.
Does the FOA support studies involving medications?
Yes. The FOA explicitly includes work that examines behavioral approaches paired with medications and supports improving adherence to addiction medications.
Does the program address treatment for people with co-occurring conditions (comorbidities)?
Yes. The FOA includes drug abuse treatment interventions for individuals with comorbidities and recognizes that many patients also face mental health disorders, medical complications, or social and structural barriers that affect outcomes.
Is treatment adherence a specific priority area?
Yes. The FOA highlights treatment adherence as a key research focus, including projects that improve engagement, retention, and consistent participation in drug abuse treatment and related care.
Are technology-enabled interventions encouraged?
Yes. Technology-enabled interventions are explicitly encouraged, especially when they strengthen outcomes and make programs easier to implement and sustain.
What are examples of how technology might be used in supported projects (based on the FOA description)?
The FOA describes technology use cases such as tools that increase adherence, extend support outside clinic visits, improve monitoring and feedback, reduce staff burden, and help maintain fidelity to an evidence-based protocol.
Does this opportunity include HIV prevention topics?
Yes. The FOA prioritizes research that addresses HIV prevention within drug abuse treatment settings, including interventions that reduce HIV acquisition or transmission risk among individuals in treatment.
Does the FOA support work related to HIV medication adherence?
Yes. It supports work aimed at improving adherence to HIV medications as well as adherence to substance use treatment and addiction medications.
Does the FOA address the relationship between substance misuse and chronic pain?
Yes. The FOA welcomes intervention development research that treats substance misuse in the context of chronic pain, with approaches that address pain management, functioning, and misuse risk simultaneously.
What stage of research is this FOA most aligned with?
The FOA notes that research of interest includes, but is not limited to, Stage I research, emphasizing early-stage behavioral treatment development activities such as refining intervention components, testing feasibility and acceptability, and generating preliminary signals of efficacy and mechanism before larger-scale trials.
What are the NIH activity areas associated with this opportunity?
The program sits within NIH health and education activity areas.
What CFDA numbers are associated with this opportunity?
The associated CFDA numbers are 93.273 and 93.279.
Who is eligible to apply?
Eligibility is broad and includes many types of U.S. organizations and government entities, as well as non-U.S. entities (foreign organizations).
Are state and local governments eligible applicants?
Yes. Eligible applicants include state governments and local governments such as county, city, or township governments, along with special district governments.
Are educational institutions eligible?
Yes. Eligible applicants include independent school districts, public and state-controlled institutions of higher education, and private institutions of higher education.
Are nonprofit organizations eligible?
Yes. Both nonprofits with 501(c)(3) status and nonprofits without 501(c)(3) status are eligible.
Are for-profit organizations eligible?
Yes. For-profit organizations (other than small businesses) and small businesses are eligible.
Are public housing authorities eligible?
Yes. Public housing authorities and Indian housing authorities are listed as eligible.
Are Tribal entities eligible?
Yes. Eligible applicants include federally recognized Native American tribal governments and Native American tribal organizations that are not federally recognized governments.
Does the FOA mention specific institution types such as HBCUs or Hispanic-serving institutions?
Yes. It calls out Alaska Native and Native Hawaiian Serving Institutions, AANAPISI institutions, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), and Tribally Controlled Colleges and Universities (TCCUs).
Are faith-based and community-based organizations eligible?
Yes. Faith-based or community-based organizations are explicitly listed as eligible applicant categories.
Are U.S. territories or possessions eligible to apply?
Yes. U.S. territories or possessions are included among eligible applicant categories.
Are federal agencies eligible to apply?
Yes. Eligible federal government agencies are listed as eligible applicants.
Are non-U.S. (foreign) organizations eligible to apply?
Yes. The FOA indicates that non-U.S. entities (foreign organizations) are eligible.
What is the original closing date listed for this opportunity?
The original closing date is 2025-05-07.
What is the creation date listed for this opportunity?
The creation date is 2025-01-22.
Is there an award ceiling listed in the provided information?
No. An award ceiling is not specified in the provided source data.
Is the expected number of awards provided?
No. The expected number of awards is not listed in the provided information.
What types of project teams is this opportunity best suited for?
It is best suited for teams developing practical, mechanism-informed behavioral or integrated interventions for substance use treatment, adherence, HIV-related risk reduction in treatment populations, and substance misuse with chronic pain, with a pathway toward optimized, implementable, and sustainable strategies.
Browse more opportunities from the same category: Education, Health
Next opportunity: FY25 Community Policing Development Microgrants
Previous opportunity: OVW Fiscal Year 2025 Local Law Enforcement Grants for Enforcement of Cybercrimes Program
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 24 300
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 24 300) also looked into and applied for these:
| Funding Opportunity |
|---|
| Development of Interventions to Prevent and Treat Substance Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional) Apply for PAR 25 446 Funding Number: PAR 25 446 Agency: National Institutes of Health Category: Education, Health Funding Amount: $3,000,000 |
| Community-Partnered Nursing Research Centers (P20 Clinical Trial Optional) Apply for PAR 25 439 Funding Number: PAR 25 439 Agency: National Institutes of Health Category: Education, Health Funding Amount: $500,000 |
| Dynamic and Adaptable Infrastructure for Drug Development and Outreach to Aid the Research Community in Advancing Medication Repurposing and Repositioning Efforts for Substance Use Disorders (SUDs) (U54 - Clinical Trials Not Allowed) Apply for RFA DA 26 020 Funding Number: RFA DA 26 020 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 24 300", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.